The Center for Biosimilars® recaps the top stories for the week of October 14, 2019.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 14, 2019.
Number 5: A pharmacists’ group has issued a global position statement in which it recommends against treating biosimilars as interchangeable.
Number 4: A new bill would amend the Affordable Care Act to allow insulins to be approved under abbreviated new drug applications as of 2020.
Number 3: The Congressional Budget Office and CMS report that the Lower Drug Costs Now Act would save on federal spending and improve health, at least in the short term.
Number 2: In a memorandum in support of its motion to dismiss an antitrust lawsuit, AbbVie said that the complaint could upend the balance between patent and antitrust laws and hurt innovation.
Number 1: Newly introduced bipartisan legislation would require HHS to evaluate Medicare Advantage plans based on whether biosimilars are available to enrollees.
Finally, last week, our e-newsletter asked whether you think that the UK Labour party’s proposal to use compulsory licensing in order to let the government develop cheaper generics is warranted.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.